Drug Therapy

Navneet S. Majhail, MBBS, MD
Department of Internal Medicine, The Cleveland Clinic

Alan E. Lichtin, MD
Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Alan E. Lichtin, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Navneet S. Majhail, MBBS, MD
Department of Internal Medicine, The Cleveland Clinic

Alan E. Lichtin, MD
Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Alan E. Lichtin, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Navneet S. Majhail, MBBS, MD
Department of Internal Medicine, The Cleveland Clinic

Alan E. Lichtin, MD
Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Alan E. Lichtin, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Francisco Alvarado-Ramy, MD
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA

Elise M. Beltrami, MD
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Address: Francisco Alvarado-Ramy, MD, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Mailstop D-18, 1600 Clifton Road, Atlanta, GA 30333

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Francisco Alvarado-Ramy, MD
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA

Elise M. Beltrami, MD
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Address: Francisco Alvarado-Ramy, MD, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Mailstop D-18, 1600 Clifton Road, Atlanta, GA 30333

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Francisco Alvarado-Ramy, MD
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA

Elise M. Beltrami, MD
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Address: Francisco Alvarado-Ramy, MD, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Mailstop D-18, 1600 Clifton Road, Atlanta, GA 30333

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center, Director Cardiology Fellowship Training Program, Co-Director, UCLA Preventative Cardiology Program, Associate Professor of Medicine, UCLA Division of Cardiology

Address: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095; e-mail: [email protected]

The author has indicated that he has received grant and research support from Pfizer, Merck, Bristol-Myers Squibb, and GlaxoSmithKline corporations.

His lecture at The Cleveland Clinic Division of Medicine Grand Rounds was funded in part by an unrestricted educational grant from Pfizer.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center, Director Cardiology Fellowship Training Program, Co-Director, UCLA Preventative Cardiology Program, Associate Professor of Medicine, UCLA Division of Cardiology

Address: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095; e-mail: [email protected]

The author has indicated that he has received grant and research support from Pfizer, Merck, Bristol-Myers Squibb, and GlaxoSmithKline corporations.

His lecture at The Cleveland Clinic Division of Medicine Grand Rounds was funded in part by an unrestricted educational grant from Pfizer.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center, Director Cardiology Fellowship Training Program, Co-Director, UCLA Preventative Cardiology Program, Associate Professor of Medicine, UCLA Division of Cardiology

Address: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095; e-mail: [email protected]

The author has indicated that he has received grant and research support from Pfizer, Merck, Bristol-Myers Squibb, and GlaxoSmithKline corporations.

His lecture at The Cleveland Clinic Division of Medicine Grand Rounds was funded in part by an unrestricted educational grant from Pfizer.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Amir Jaffer, MD
Medical Director, Anticoagulation Clinic, and the IMPACT (Internal Medicine Preoperative Assessment and Consultation) Center, The Cleveland Clinic. The Anticoagulation Clinic currently cares for more than 1,600 patients on warfarin.

Lee Bragg, PharmD
Coordinator, Anticoagulation Clinic, Department of General Internal Medicine and Department of Pharmacy, The Cleveland Clinic

Address: Amir Jaffer, MD, Department of General Internal Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Dr. Jaffer has indicated that he is on the speakers’ bureau of the Bristol-Myers Squibb (formerly DuPont Pharmaceutical) and Aventis corporations. He is also a consultant to Aventis and AstraZeneca and has received grant or research support from AstraZeneca.

Dr. Bragg has indicated that he has received grant or research support from DuPont Pharmaceuticals.

Amir Jaffer, MD
Medical Director, Anticoagulation Clinic, and the IMPACT (Internal Medicine Preoperative Assessment and Consultation) Center, The Cleveland Clinic. The Anticoagulation Clinic currently cares for more than 1,600 patients on warfarin.

Lee Bragg, PharmD
Coordinator, Anticoagulation Clinic, Department of General Internal Medicine and Department of Pharmacy, The Cleveland Clinic

Address: Amir Jaffer, MD, Department of General Internal Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Dr. Jaffer has indicated that he is on the speakers’ bureau of the Bristol-Myers Squibb (formerly DuPont Pharmaceutical) and Aventis corporations. He is also a consultant to Aventis and AstraZeneca and has received grant or research support from AstraZeneca.

Dr. Bragg has indicated that he has received grant or research support from DuPont Pharmaceuticals.

Amir Jaffer, MD
Medical Director, Anticoagulation Clinic, and the IMPACT (Internal Medicine Preoperative Assessment and Consultation) Center, The Cleveland Clinic. The Anticoagulation Clinic currently cares for more than 1,600 patients on warfarin.

Lee Bragg, PharmD
Coordinator, Anticoagulation Clinic, Department of General Internal Medicine and Department of Pharmacy, The Cleveland Clinic

Address: Amir Jaffer, MD, Department of General Internal Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Dr. Jaffer has indicated that he is on the speakers’ bureau of the Bristol-Myers Squibb (formerly DuPont Pharmaceutical) and Aventis corporations. He is also a consultant to Aventis and AstraZeneca and has received grant or research support from AstraZeneca.

Dr. Bragg has indicated that he has received grant or research support from DuPont Pharmaceuticals.

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

Thomas F. Keys, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Thomas F. Keys, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Thomas F. Keys, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Thomas F. Keys, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Thomas F. Keys, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Thomas F. Keys, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]